Allergan to file ubrogepant for migraine early next year
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Read More
Tag: CGRP receptor
EU regulators review Novartis’ migraine drug
An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
